<qa>  What is the STUDY OF TANDUTINIB?A PHASE 2 STUDY OF TANDUTINIB IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA WHO ARE CONSIDERED INELIGIBLE FOR OR WHO DECLINE TREATMENT WITH STANDARD INDUCTION THERAPY: 